IOVAIovance Biotherapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$74M+15189.2% YoY

Gross Profit

$28M38.2% margin

Operating Income

-$87M-117.5% margin

Net Income

-$79M-106.6% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+25.9%

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$77M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$910M

Total Liabilities

$200M

Stockholders' Equity

$710M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$74M	$482,000	+15189.2%
Gross Profit	$28M	-$4M	+825.0%
Operating Income	-$87M	-$121M	+28.6%
Net Income	-$79M	-$116M	+32.5%

Geographic Segments

UNITED STATES

$103M98%

Non-US

$2M2%

IOVA Q4 2024 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena